Nonsignificant survival benefit seen for dabrafenib, trametinib in melanoma
For patients with resected stage III melanoma, adjuvant therapy with dabrafenib plus trametinib is associated with a nonsignificant benefit in terms of overall survival, according to a study published in the New England Journal ...
Jun 24, 2024
0
0